Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure until the safety concerns for cibotercept are resolved.
Kerros stock plummeted more than 70% premarket Thursday and Truist Securities analysts predict it will remain under pressure until the safety concerns for cibotercept are resolved.